These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33067337)

  • 1. Effects of Repeated
    Yoshinaga K; Abe T; Okamoto S; Uchiyama Y; Manabe O; Ito YM; Tamura N; Ito N; Yoshioka N; Washino K; Shinohara N; Tamaki N; Shiga T
    J Nucl Med; 2021 May; 62(5):685-694. PubMed ID: 33067337
    [No Abstract]   [Full Text] [Related]  

  • 2. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of (131)Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders.
    Mulholland N; Chakravartty R; Devlin L; Kalogianni E; Corcoran B; Vivian G
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2002-12. PubMed ID: 26142730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response.
    Buscombe JR; Cwikla JB; Caplin ME; Hilson AJ
    Nucl Med Commun; 2005 Nov; 26(11):969-76. PubMed ID: 16208174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring the efficacy of iodine-131-MIBG therapy using fluorine-18-FDG-PET.
    Menzel C; Graichen S; Berner U; Risse JH; Diehl M; Döbert N; Hamscho N; Grünwald F
    Acta Med Austriaca; 2003; 30(2):37-40. PubMed ID: 12752086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
    Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
    J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
    Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
    Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of using a standard activity of (131)I-MIBG therapy in patients with disseminated neuroendocrine tumours.
    Navalkissoor S; Alhashimi DM; Quigley AM; Caplin ME; Buscombe JR
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):904-12. PubMed ID: 20016892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
    Castellani MR; Chiti A; Seregni E; Bombardieri E
    Q J Nucl Med; 2000 Mar; 44(1):77-87. PubMed ID: 10932604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with
    Kane A; Thorpe MP; Morse MA; Howard BA; Oldan JD; Zhu J; Wong TZ; Petry NA; Reiman R; Borges-Neto S
    J Nucl Med; 2018 Nov; 59(11):1708-1713. PubMed ID: 29777005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodistribution and Dosimetry of
    Pandit-Taskar N; Zanzonico P; Staton KD; Carrasquillo JA; Reidy-Lagunes D; Lyashchenko S; Burnazi E; Zhang H; Lewis JS; Blasberg R; Larson SM; Weber WA; Modak S
    J Nucl Med; 2018 Jan; 59(1):147-153. PubMed ID: 28705916
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.
    Ezziddin S; Sabet A; Logvinski T; Alkawaldeh K; Yong-Hing CJ; Ahmadzadehfar H; Grünwald F; Biersack HJ
    J Nucl Med; 2013 Dec; 54(12):2032-8. PubMed ID: 24101685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 131I-MIBG Therapy in a Metastatic Small Bowel Neuroendocrine Tumor Patient Undergoing Hemodialysis.
    Rahimi B; Makis W; Riauka TA; McEwan AJ; Morrish D
    Clin Nucl Med; 2017 May; 42(5):350-353. PubMed ID: 28240668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
    Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
    J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
    Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
    Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Equivalent Dose Rate 1 Meter from Neuroendocrine Tumor Patients Exiting the Nuclear Medicine Department After Undergoing Imaging.
    Zhang-Yin J; Dirand AS; Sasanelli M; Corrégé G; Peudon A; Kiffel T; Nataf V; Clerc J; Montravers F; Talbot JN
    J Nucl Med; 2017 Aug; 58(8):1230-1235. PubMed ID: 28209907
    [No Abstract]   [Full Text] [Related]  

  • 20. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans.
    Monsieurs M; Brans B; Bacher K; Dierckx R; Thierens H
    Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1581-7. PubMed ID: 12458391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.